
News|Articles|January 1, 2004
As post-tamoxifen therapy, letrozole cuts breast cancer recurrence 43%
Letrozole therapy, in follow-up to 5 years of tamoxifen treatment, significantly improves disease-free survival compared to placebo, according to a study published in The New England Journal of Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
2
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































